Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q4 2019 Earnings Conference Call March 12, 2020 8:30 AM ET Company Participants Ted Jenkins - Senior Director, Investor Relations and Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer and Head, Research Craig Millian - Chief Commercial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Maury Raycroft - Jefferies Leland Gershell - Oppenheimer Operator Good morning and welcome to the C ...

CORBUS PIONEERING TRANSFORMATIVE MEDICINES THAT TARGET THE ENDOCANNABINOID SYSTEM NASDAQ: CRBP | corbuspharma.com | @corbuspharma | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - Corbus Pharmaceuticals ended Q3 2019 with approximately $55 million in cash, which is expected to be sufficient to support operations through key data readouts and into Q3 2020 [18] Business Line Data and Key Metrics Changes - The RESOLVE-1 global Phase 3 study of lenabasum in systemic sclerosis is fully enrolled with 365 patients dosed, with top-line data expected next summer [7] - The DETERMINE global Phase 3 study of lenabasum in dermatomyositis is actively enrolling subjects, with expectations to complete enrollment in 2020 and top-line results in 2021 [8] - The 415 patient Phase 2b study in cystic fibrosis is ongoing, with top-line data expected in summer 2020 [10] Market Data and Key Metrics Changes - Market research indicates a strong need for new anti-inflammatory treatments in cystic fibrosis, particularly for patients with established lung disease who continue to experience exacerbations [16] Company Strategy and Development Direction - The company is focused on preparing for the commercial launch of lenabasum, building a commercial leadership team, and establishing market insights [14] - Corbus aims to explore additional partnerships abroad, particularly in Asia, to increase global reach [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding upcoming data from Phase 3 studies and the potential for lenabasum to reshape treatment paradigms for inflammatory and fibrotic diseases [6][18] - The company is preparing for a successful launch and is actively engaging with patients and physicians to understand the unmet needs in systemic sclerosis and cystic fibrosis [15][16] Other Important Information - The second drug in the pipeline, CRB-4001, is targeting NASH with fibrosis, with a Phase 1 safety study scheduled for readout in 2020 [11] - The company highlighted eight promising compounds at their R&D Day, which are progressing through candidate selection [11] Q&A Session Summary Question: Key learnings from systemic sclerosis patients on treatment and expectations for ACR data - Management expects to see a favorable long-term safety profile and durable efficacy data in the upcoming ACR presentation [23] Question: Impact of recent changes in standard of care on the Phase 2b study in cystic fibrosis - Management believes lenabasum will offer treatment benefits on top of existing standard care treatments, and they are prepared for statistical sensitivity analysis [25] Question: Updates on formulation work for CRB-4001 and timelines for PET data - Management is optimistic about the formulation for CRB-4001 and expects to have readouts from the Phase 1 study in 2020, but timelines for PET data remain uncertain [30] Question: Focus areas for ACR updates and competitive landscape - Management highlighted the importance of safety and efficacy data in their presentations at ACR, and they expect to be the first to seek approval for systemic sclerosis treatments [36] Question: Progress on preclinical CB programs and potential partnerships - Management indicated that they are making progress with their internal compounds and anticipate moving forward with candidate selection in the coming months [38]

Pioneering transformative medicines that target the endocannabinoid system NASDAQ: CRBP @corbuspharma www.corbuspharma.com TM Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0001 per share CRBP Nasdaq Global Market Emerging growth company [X] FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period September 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q2 2019 Earnings Conference Call August 8, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director, Investor Relations & Corporate Communications Yuval Cohen - Chief Executive Officer Barbara White - Chief Medical Officer Craig Millian - Chief Commercial Officer. Conference Call Participants Brian Abrahams - RBC Liisa Bayko - JMP Securities Maury Raycroft - Jefferies Ted Tenthoff - Piper Jaffray George Zavoico - B. Riley FBR Operator Good mornin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period June 30, 2019 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________. Commission File Number: 001-37348 Corbus Pharmaceuticals Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 46-4348039 (State ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible or ...

Vision: Become the Leader in the Treatment of Inflammatory and Fibrotic Diseases by Targeting the Endocannabinoid System with the Industry's Leading Pipeline NASDAQ: CRBP @corbuspharma www.corbuspharma.com NASDAQ: CRBP @corbuspharma www.corbuspharma.com Forward-Looking Statements 2 This presentation contains certain forward-looking statements, including those relating to the Company's product development, clinical trials, clinical and regulatory timelines, market opportunity, competitive position, possible ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Q1 2019 Earnings Conference Call May 9, 2019 8:30 AM ET Company Participants Ted Jenkins - Senior Director of IR and Corporate Communications Yuval Cohen - CEO Barbara White - Chief Medical Officer Conference Call Participants Maury Raycroft - Jefferies Leland Gershell - Oppenheimer and Company George Zavoico - B. Riley FBR Operator Greetings, and welcome to the Corbus Pharmaceuticals Quarterly Update Conference Call and Webcast. At this time, all particip ...